

4 issues/year · approx. 70 pages · 2511-7157 · print and online · [www.lexxion.eu/ehpl](http://www.lexxion.eu/ehpl)

EUROPEAN HEALTH & PHARMACEUTICAL LAW REVIEW (EHPL)

## SPECIAL ISSUE

### European Pharmaceutical Strategy

The European Commission's Pharmaceutical Strategy for Europe adopted on 25 November 2020. The Strategy aims to create a future-proof regulatory framework that supports the industry, addressing market failures and promoting technologies that meet patients' needs. The Strategy advances a number of proposals for legislative reform that will profoundly change the way medicines and medical devices are regulated in Europe. This special edition will focus on the Strategy's aims and implications.

We welcome contributions on any topics relating to the Strategy, especially:

- **Unmet medical needs, accessibility & affordability of medicine**
- **Digital transformation**
- **Flexible regulatory systems**
- **Resilience of the European Pharma sector**
- **Cooperation and implementation of EU's pharmaceutical strategy**

We are accepting: a) short reports on or visions for the Strategy (up to 3000 words); and b) longer, research articles (up to 8000 words). All contributions will be subject to double-blind peer-review before acceptance for publication and are required to conform to the author guidelines available at:  
[www.lexxion.eu/ehpl/#authors](http://www.lexxion.eu/ehpl/#authors).

The most thought-provoking report/vision and the most compelling research article will be invited to present at a webinar hosted by the Center for Advanced Studies in Biomedical Innovation Law (University of Copenhagen).

**Green and Gold Open Access options are available.**



Send submissions to:

**Jakob McKernan**

Executive Editor

[mckernan@lexxion.eu](mailto:mckernan@lexxion.eu)

+49-30-81 45 06-10

#### Managing Editor

Jakob Wested  
University of Copenhagen

#### Editorial Board

Ulrich M. Gassner  
University of Augsburg  
Richard S. Goldberg  
Durham University  
Leigh Hancher,  
University of Tilburg / Baker Botts  
Isabelle Huys  
KU Leuven  
Tomasz Jablonski  
European Medicines Agency  
Els Janssens  
Baker McKenzie  
Trudo Lemmens  
University of Toronto  
Robert Madelin  
Foresight International Policy and Regulatory  
Advisers  
Timo Minssen  
University of Copenhagen  
Marco de Morpurgo  
DLA Piper / HEC Paris  
Vincenzo Salvatore  
University of Insubria/BonelliErede  
Santa Slokenberga  
Uppsala University  
George Peretz  
Monckton Chambers  
Claudia Seitz  
University of Ghent  
Eveline Van Keymeulen  
Latham & Watkins

#### Executive Editor

Jakob McKernan  
Lexxion Publisher, Berlin